Grid 1M Tablet PR is a combination oral antidiabetic medication containing Glimepiride 1mg and Metformin 500mg, indicated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class agent, enhances pancreatic beta-cell insulin secretion, thereby improving glycemic control. Metformin, a biguanide, primarily reduces hepatic glucose production and increases peripheral insulin sensitivity, contributing to improved glucose uptake and utilization. The combination of these two agents provides complementary mechanisms to achieve better glycemic control in patients inadequately controlled by diet and exercise alone. Grid 1M Tablet PR is generally prescribed when monotherapy with either agent is insufficient. It is essential to initiate therapy with appropriate lifestyle modifications, including diet and exercise. The medication should be taken as directed by a healthcare professional, typically with meals to minimize gastrointestinal side effects associated with Metformin. Regular monitoring of blood glucose levels, renal function, and hepatic function is recommended during treatment. Caution is advised in patients with renal impairment, hepatic dysfunction, or conditions predisposing to hypoglycemia. Common adverse effects may include hypoglycemia, gastrointestinal disturbances, and, rarely, lactic acidosis. Patient adherence and periodic evaluation are critical to optimizing therapeutic outcomes with Grid 1M Tablet PR.